04/07/2023
Stablepharma publishes ground-breaking, peer-reviewed article on world’s first fridge-free Tetanus diphtheria (Td) vaccine.
The Challenge: In the world of vaccine storage and distribution, maintaining an unbroken ‘cold chain’, for years in the case of Td adult booster vaccines, is an enormous challenge to preserve the potency and efficacy of live-saving vaccines. Almost all vaccines, even the most modern nucleic acid-based types, need constant refrigeration during transportation from the factory to the patient.
However, this causes considerable challenges and cost implications for stockpiling and distribution around the world. This is especially true for modern nucleic acid-based vaccine, which have proven to be very effective but also very fragile.
The ongoing wastage and logistical challenges of the cold chain are made even more difficult by the need to transport vaccines to parts of the world with poor infrastructures and unreliable refrigeration. Adult booster vaccines (including Td) have to be stored in controlled temperatures for years, before being administered to a person.
The Solution: Stablepharma’s novel technology platform, StablevaX™ creates fridge-free vaccines by converting existing approved vaccines to a thermostable status, thereby eliminating the need for the global cold chain, reducing vaccine wastage and saving lives.
Stablepharma’s scientific publication, which was published by the prestigious journal Vaccine (Elsevier) Volume 41, Issue 22, May 2023 presents their fridge-free, single-dose, thermostable vaccine (STVX-01) that has been developed in a pre-dosed vial used for vaccination. Full recovery of vaccine potency, after 7–10 months at 45°C, was shown by complete protection against supra-lethal doses of active toxins.
https://stablepharma.com/publications/
